For Physicians

Domenica M. Rubino, MD is board certfied by The American Board of Obesity Medicine, The American Board of Endocrinology, Diabetes and Metabolism and The American Board of Internal Medicine.

A significant number of patients in your practice are dealing with health issues directly connected with obesity. Many physicians express frustration in not having the time and resources to help their patients with their weight. We can help you and your patients. For a more in-depth explanation of our services and to see some of our results please go to our services page.

Controversial Issues and Challenging Cases in the New Frontier of Obesity Online Activity - from medtelligence.net

Clinical Research

We have participated in research collaborations with the following Institutes: NIH, Medical University of South Carolina, GW University Division of Exercise Science, Georgetown University, University of MD and USUHS. As an investigative team for the development of pharmaceuticals for the treatment and management of obesity, we have worked with the following companies: Abbott, Amgen, Arena Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Eisai, Elcelyx, Merck & Co., Medtronic, Nazura, Novo Nordisk, Orexigen Therapeutics, R.W. Johnson, Sanofi-Synthelabo, Schering Plough, Takeda and Vivus.

Our involvement in clinical research that has resulted in several recent articles:

  • Abraham-Baid S, Abel BS, Rubino D, Nansel T, Ramsey S, and Nieman L. A direct comparison of quality of life in obese and Cushing's syndrome patients. Eur J Endocrinol., 26 February 2013, 168(5) 787-793.
  • Abraham-Baid S, Rubino DM, Sinaii N, Ramsey SA, Nieman LK. Cortisol, obesity and the metabolic syndrome: A cross-sectional study of obese subjects and review of the literature. Obesity, January 2013; 21(1): E105-117.
  • Apovian CM, Aronne LJ, Rubino DM, Still CD, Wyatt H, Burns C, Kim DD, Dunayevich E. Effects of Naltrexone SR/Bupropion SR Combination Therapy on Weight loss and Obesity-related Risk Factors in Overweight and Obese Participants: The COR-II Phase 3 Trial. Obesity, May 2013; 21(5) 935-943.
  • Rubino DM, Gadde KM. A review of topiramate and phentermine: a combined therapeutic approach for obesity. Clin. Lipidol., Feb 2012; 7(1): 1-13.

Referrals

We offer courtesy billing to our patients with private health insurance plans. Our patients are typically getting reimbursed between 10 and 60 percent of their out-of-pocket expenses throughout the time that they are with us.

If you have specific questions about our clinical weight loss or research programs, please give us a call. We would be happy to send over brochures for your patients who might be interested in learning more about our programs.

Specialists will work collaboratively with you for any patients whom you refer to the Center. With your patient’s permission, we will send you updates regarding your patient’s progress or medical issues that arise during participation in our programs.